Increased expression of class III β-tubulin in castration-resistant human prostate cancer by Terry, S et al.
Increased expression of class III b-tubulin in castration-resistant
human prostate cancer
S Terry*,1,2,3, G Ploussard
1,2, Y Allory
1,2,4, N Nicolaiew
1,2, F Boissie `re-Michot
5, P Maille ´
4, L Kheuang
1,2,
E Coppolani
1, A Ali
1, F Bibeau
5, S Culine
1,2,4, R Buttyan
6, A de la Taille
1,2,4 and F Vacherot
1,2
1INSERM, Unite ´ 955, Cre ´teil F-94000, France;
2Universite ´ Paris 12, Faculte ´ de Me ´decine, Cre ´teil F-94000, France;
3Universite ´ Paris-Sud 11, Faculte ´ de
Me ´decine, Le Kremlin-Bice ˆtre F-94276, France;
4AP-HP, Groupe Henri Mondor-Albert Chenevier, Service de Pathologie et Urologie, Cre ´teil F-94000,
France;
5Centre Val d’Aurelle, Service de Pathologie, Montpellier F-34298, France;
6Cancer Center, The Ordway Research Institute, Albany, NY 12208,
USA
BACKGROUND: Class III b-tubulin (bIII-tubulin) is expressed in tissues of neuronal lineage and also in several human malignancies,
including non-small-cell lung carcinoma, breast and ovarian cancer. Overexpression of bIII-tubulin in these tumours is associated with
an unfavourable outcome and resistance to taxane-based therapies. At present, bIII-tubulin expression remains largely
uncharacterised in prostate cancer.
METHODS: In this report, we evaluated the expression of bIII-tubulin in 138 different human prostate tumour specimens by
immunohistochemistry from patients with hormone-treated or hormone-untreated prostate cancer. bIII-tubulin expression was also
examined in various prostatic cancer cell lines including in androgen-sensitive human prostate cancer cells, LNCaP, grown in
androgen-depleted medium in 2D cultures or as tumour xenografts when the host mouse was castrated.
RESULTS: Whereas moderate-to-strong bIII-tubulin expression was detected in only 3 out of 74 (4%) hormone-naive tumour
specimens obtained from patients who never received hormone therapy, 6 out of 24 tumour specimens (25%) from patients treated
for 3 months with neoadjuvant hormone therapy and 24 out of 40 (60%) castration-resistant tumour specimens from chronic
hormone-treated patients were found to express significant levels of bIII-tubulin. These findings were supported by in vitro and in vivo
settings.
CONCLUSION: Our data indicate that bIII-tubulin expression is augmented in prostate cancer by androgen ablation and that the
expression of this b-tubulin isoform is associated with the progression of prostate cancer to the castration-resistant state, a stage
largely responsible for mortality from prostate cancer.
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Prostate carcinoma (PCa) is the most common malignancy and the
second leading cause of cancer death in men (Ferlay et al, 2007;
Jemal et al, 2008). Despite the current widespread use of prostate-
specific antigen (PSA) screening that increases the detection of
PCa at an early stage when it is localised to the prostate, B30% of
men treated with surgical or radiation therapies will relapse (Han
et al, 2001). These men and those who present with locally
advanced or overt metastatic PCa are treated by hormonal
therapies that deplete circulating androgen levels (Hellerstedt
and Pienta, 2002). For most men with advanced PCa, hormone
therapy provides a median progression-free survival of 12–33
months until the emergence of a castration-resistant prostate
cancer (CRPC) that is refractory to the low androgen levels of the
hormone-treated patient. As CRPC generally responds poorly to
alternate therapeutics, this form of the disease is overwhelmingly
responsible for mortality from PCa.
Recently, however, treatments involving docetaxel-based chemo-
therapy have shown some benefit for CRPC, although the survival
advantage remains relatively limited (Petrylak et al, 2004; Tannock
et al, 2004). Taxanes, of which docetaxel is a derivative, target the
microtubules of cancer cells to disrupt the mitotic apparatus
leading to cancer cell death. Microtubules are composed of
polymers of a- and b-tubulin heterodimers (Orr et al, 2003; Seve
and Dumontet, 2008). Both a- and b-tubulins exist as multiple
isotypes with a complex pattern of distribution among different
tissues. Class III b-tubulin (bIII-tubulin) is normally expressed in
neuronal tissues and in neuroendocrine (NE) cells, and this
isoform of b-tubulin is also expressed in some solid tumours,
including tumours of neuronal origin and non-small-cell lung,
gastric, breast and ovarian carcinomas. For these latter tumours,
the expression of bIII-tubulin correlates with a poor overall
survival as well as with reduced response to taxanes (Ferrandina
et al, 2006; Gan et al, 2007; Galmarini et al, 2008; Seve and
Dumontet, 2008). Indeed, resistance to taxanes can be induced in
cultured human tumour cells by transfection with bIII-tubulin,
whereas bIII-tubulin depletion in cells resulted in the sensitisation
to taxanes (Lu and Luduena, 1993; Panda et al, 1994; Kavallaris
et al, 1999; Kamath et al, 2005; Shalli et al, 2005; Gan et al, 2007).
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cell microtubules alters their sensitivity to taxane-based agents.
At present, the expression of bIII-tubulin remains relatively
uncharacterised in PCa. One study did assess bIII-tubulin expres-
sion in a small group of localised PCa specimens by immuno-
histochemistry and reported that bIII-tubulin was moderately
expressed in both benign and malignant tissues cells of the
prostate (Ranganathan et al, 1997). However, this evaluation did
not include analysis of castration-resistant disease, which is the
actual candidate for standard chemotherapeutic intervention. In
this study, we provide evidence, on the basis of immunostaining
profiles of different classes of prostate tumours, that bIII tubulin
expression is highly upregulated in prostate cancer cells during the
transition from hormone-sensitive to the castration-resistant state.
Whereas this characterisation might help to better explain the
more aggressive and therapeutic-resistant nature of CRPC, it also
has implications for the use of alternative microtubule-targeting
therapeutic agents that might be more effective than docetaxel in
the treatment of CRPC.
MATERIALS AND METHODS
Human prostate tissue samples
Formalin-fixed, paraffin-embedded prostate tissues were obtained
from the Department of Pathology at the Henri Mondor Hospital
and from the Cancer Centre in Montpellier, France. Pathological
specimens of hormone-naive (HNPC; n¼74) and hormone-
therapy-treated (HTPC; n¼24) prostate cancers used in this study
were obtained from patients treated for localised disease by radical
prostatectomy. Hormone-therapy-treated prostate cancer cases
comprised patients who had been treated with 3 months of
neoadjuvant therapy with LHRH agonists before surgery. Meta-
static CRPC (n¼6) tissues were liver biopsy samples collected
from patients diagnosed with liver metastases as the first site of
metastatic disease. Primary CRPC specimens (n¼34) were
collected at the time of the trans-urethral resection of the prostate
in patients who experienced disease recurrence after an initial
response to hormone therapy. Recurrence was defined as patients
having PSA progression despite a complete androgen blockade
therapy and a castrated level of testosterone. All samples were
obtained with institutional review board approval from the
respective institutions.
Immunohistochemical analysis
Immunohistochemistry was carried out on tissue microarrays
(TMAs) containing samples (primary CRPC and HNPC cases) and
regular sections (HNPC (10 cases), primary CRPC, HTPC and
biopsy samples). For TMA, four replicate cores (with diameter of
0.6mm) were collected from the donor block. bIII-tubulin protein
expression was assessed after standard biotin–avidin complex
immunohistochemistry using a monoclonal antibody against bIII-
tubulin (1:500; clone TUJ1; Covance, Emeryville, CA, USA).
Protein expression was scored as null (0), weak (1), moderate (2)
and strong (3). In this analysis, a case was considered positive only
when the score was X2 in more than 10% of cancer cells, whereas
cases with o10% staining or those that scored o2 were
considered negative. bIII-tubulin expression was evaluated sepa-
rately by one pathologist (YA) and by two non-pathologists (ST
and GP). The staining assessment was highly reproducible.
Immunostains obtained from regular sections of CRPC and HNPC
samples were constantly comparable with those obtained in the
TMA analysis. Positivity in nerves and axons present in the
sections served as positive control. Negative controls were
included in each experiment in which the primary antibody was
omitted. The absence of immunostaining in red cells was also used
as a negative control as previously described (Ranganathan et al,
1997). The following antibodies were used to assess the NE
characteristics of the specimens: polyclonal antibodies to chromo-
graninA (CgA; Dako, Trappes, France; A0430); monoclonal
antibodies to synaptophysin (Snp88, Biogenex, San Ramon, CA,
USA) and NSE (BBS/NC/VI-H14, Dako).
Cell culture
Human prostate cancer cell lines LNCaP (clone FGC), 22Rv1, PC3
and DU145 were obtained from American Type Culture Collection
(Manassas, VA, USA), and the cells were maintained in RPMI 1640
supplemented with 10% fetal bovine serum (FBS) and penicillin/
streptomycin. For androgen-reduced conditions, LNCaP cells
were cultured in phenol red-free RPMI supplemented with 10%
charcoal-stripped FBS for the indicated time in the presence
or absence of Dihydrotestosterone (DHT, Sigma-Aldrich, Saint-
Quetin Fallavier, France).
Western blot analysis
Protein lysates were prepared in the RIPA buffer (radioimmuno-
precipitation assay lysis buffer) supplemented with protease inhibitor
cocktail (Roche Diagnostics, Basel, Switzerland) and phosphatase
inhibitors (25mmoll
 1 orthovanadate and 50mmoll
 1 NaF) (Sigma-
Aldrich). The total protein concentration of the soluble extract was
determined using the Bicinchoninic Acid Kit (Sigma-Aldrich). Each
protein sample (30mg) was resolved to SDS–PAGE, transferred onto
a polyvinylidene difluoride membrane (Millipore, Molsheim, France)
and incubated with a monoclonal antibody against bIII-tubulin
(1:10000) or b-actin (1:16000; AC-15; Sigma-Aldrich). Immune
complexes were visualised by enhanced chemiluminescence detec-
tion (ECL plus kit, GE Healthcare, Little Chalfont, UK).
cDNA synthesis and real-time PCR
Quantitative PCR was carried out using SYBR Green dye on
an Applied Biosystems 7000 Real Time PCR system (Applied
Biosystems, Foster City, CA, USA). The conditions for RT–PCR
have been described previously (Azoulay et al, 2008). The amount
of bIII-tubulin mRNA levels relative to the housekeeping gene
Ribosomal Protein, large, P0 (RPLP0) was determined on the basis
of the comparative threshold cycle CT method (2
 DDCT). The
primer sequences for bIII-tubulin and RPLP0 have been described
previously (Azoulay et al, 2008; Frigo and McDonnell, 2008).
Tumour xenografts in athymic mice
2 10
6 LNCaP cells at low passage (P29) were inoculated s.c. with
0.1ml of Matrigel (Becton Dickinson Labware, Le-Pont-de-Claix,
France) in the flank region of 6-week-old male athymic nude mice
(Elevage Janvier – Le Genest-Saint-Isle, France) under anaesthesia.
Mice bearing tumours between 200 and 300mm
3 were killed or
were surgically castrated through scrotal incision. At the indicated
days, LNCaP xenografts were processed after killing to evaluate
bIII-tubulin expression. All animal procedures were carried out
according to local guidelines on animal care and with appropriate
institutional certification.
Statistical analysis
w
2 or Fisher’s exact tests were used to assess associations between
hormone and bIII-tubulin status in human specimens. For post hoc
comparisons, the Bonferroni correction was applied. To evaluate
trend over hormone status, w
2 for trend was calculated. Immuno-
chemistry scoring results of xenografts LNCaP tumours stained
for bIII-tubulin were analysed using Kruskal–Wallis and Mann–
Whitney tests. All statistical tests used a two-tailed a¼0.05 level
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version 9.1 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Expression of bIII tubulin is predominantly expressed in
castration-resistant human prostate cancer
A total of 138 different cases of prostatic carcinoma were evaluated in
this study. The tumours included 74 specimens of HNPC found in
prostatectomy specimens obtained from patients who had never
received any form of hormonal therapy, 24 cases of HTPC specimens
from patients who received 3 months of adjuvant hormonal therapy
before radical prostatectomy and 40 cases of CRPC specimens of
which 34 were surgically removed from the prostate to relieve
bladder outlet obstruction and 6 cases of castration-resistant liver
metastases. All specimens were present in formalin-fixed and
paraffin-embedded surgical tissues. The tissues were sectioned and
were subsequently immunostained for bIII-tubulin using a standard
immunoperoxidase-based procedure.
In the HNPC group, accounting for more than half of the
specimens, the presence of bIII-tubulin expression in cancer cells
was relatively rare (Table 1 and Figure 1A). Of these 74 cases, 67
were scored as completely negative (0) and only 3 cases (4%) were
considered to be positive, scoring from moderate-to-strong for
bIII-tubulin in the cancer cells. With the exception of occasional
stained cells in the basal compartment, bIII-tubulin expression was
not detected in either normal basal cells or luminal prostate
epithelial cells present in these specimens. The extremely small
number of positively stained specimens in this group prevented us
from deriving any statistically reliable association with other
patient prognostic factors. Of the 24 cases of HTPC evaluated in
our study, 6 (25%) were considered to be positive with bIII-tubulin
immunoreactivity in the moderate-to-strong range in more than
10% of cancer cells (Table 1). Nine cases of HTPC showed
complete negative (0) staining, whereas nine other cases in this
category were scored as weak or contained only rare (o10%)
tumour cells positively stained, and this later group was also
recorded as negative. For the overall HTPC group, bIII-tubulin
expression was found to be significantly higher when compared
with the HNPC group as evaluated by Fisher’s exact test applying
the Bonferroni correction (P¼0.0186).
Finally, of the 40 specimens of CRPC that were analysed,
the majority (24 or 60%) was considered to be positive (Figure 1A
and C). The predominant staining pattern for CRPC specimens
was strong and diffuse. Only three cases of CRPC showed a
complete absence of staining (see Supplementary Table 1).
Statistical analysis of the data showed that the expression of
bIII-tubulin was significantly correlated with the castration-
resistant phenotype (Po0.000001). A further analysis with a
trend test also reached statistical significance (Po0.0001). It is
noteworthy that, bIII-tubulin protein was also expressed in cancer
cells of metastatic CRPC lesions present in the liver of patients
(Figure 1C). Indeed, the fact that we were able to detect bIII-
tubulin-positive cancer cells in at least five of six cases of this class
suggests that the deregulated expression of bIII-tubulin in CRPC
disease is not restricted to recurrent lesions localised to the
prostate. This finding is also important because metastatic lesions
are mainly responsible for both morbidity and mortality of CRPCs.
Cumulatively, these results indicate that bIII-tubulin expression
in human prostate cancer cells is upregulated by hormone therapy
and increased further when tumours progress to a castration-
resistant stage.
Table 1 bIII-tubulin expression before and after hormone therapy
bIII-tubulin
negative
bIII-tubulin
positive
Prostate carcinoma
No. of
samples (%)
No. of
samples (%)
Hormone-naive PCa (HNPC) 71 (95.9) 3 (4.1)
Hormone-therapy-treated PCa (HTPC) 18 (75) 6 (25)
Castration-resistant PCa (CRPC) 16 (40) 24 (60)
Pearson’s w
2 test: Po0.00001
Fisher’s exact test:
HNPC/HTPC P¼0.0186
HTPC/CRPC P¼0.0285
HNPC/CRPC Po0.000001
Abbreviation: PCa¼prostate carcinoma. w
2 and Fisher’s exact tests were used to
assess associations between hormone and bIII-tubulin status. For post hoc
comparisons, the Bonferroni correction was applied. All statistical tests used a
two-tailed a¼0.05 level of significance.
Figure 1 bIII-tubulin expression in prostate cancers. (A–C) Representative tissue microarray element, regular section or biopsy sample stained with
antibody to bIII-tubulin with immunostains showing the absence of staining in hormone-naive prostate cancer (panel A) and strong staining in primary
(panel B) and metastatic (panel C) castration-resistant refractory prostate cancers. (D and E) Representative consecutive sections stained with antibodies to
bIII-tubulin (panel D) or NSE (panel E). Immunostainings show concomitant bIII-tubulin and NSE expression in prostate cancer cells. (F) Prostatic small cell
carcinoma showing strong immunoreactivity for bIII-tubulin. Original magnification  200; inset,  25.
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sExpression of bIII tubulin is upregulated by hormone
therapy in human prostate cancer LNCaP cells and LNCaP
tumours
bIII-tubulin is commonly expressed in normal neural tissues and
in NE cells (Katsetos et al, 2000, 2003). In line with this
information, the results showing that bIII-tubulin expression that
was upregulated in PCa cells obtained from both acute and chronic
hormone-treated patients might be a manifestation of the NE
trans-differentiation phenomenon that has been associated with
prostate cancer cells capable of surviving in a low-androgen
environment (Yuan et al, 2007). For further exploration of this
event, 22 bIII-tubulin-positive CRPC specimens were immuno-
stained with antibodies directed against NE markers; namely CgA,
synaptophysin (SYN) and NSE. In 6 out of 22 cases analysed, we
were able to detect areas showing strong positivity for both bIII-
tubulin and NSE (Figure 1D and E). In line with this finding, 2 out
of 10 evaluable cases demonstrated concomitant bIII-tubulin and
SYN expression. However, we failed to find any co-expression
pattern when using antibodies directed against CgA (eight
evaluable cases). It is noteworthy that, bIII-tubulin expression
was also examined in one case of prostatic small cell carcinoma, an
uncommon subtype of PCa with predominance of the NE
phenotype (Yao et al, 2006). In this case, 100% of cancer cells
expressed high levels of bIII-tubulin (Figure 1F).
A trans-differentiation phenomenon is observed in cultured
androgen-sensitive PCa cells when they are maintained in a
medium depleted of androgens (Burchardt et al, 1999), and
therefore we examined, using western blot analysis, whether
androgen-sensitive human prostate cancer LNCaP cells upregulate
bIII-tubulin when they are switched to androgen-deficient
medium. Figure 2A shows that the steady-state levels of
bIII-tubulin protein were strikingly elevated in the days following
growth in the androgen-depleted medium with persistent expres-
sion detected up to 3 months under these conditions. The ability of
growth in the androgen-depleted medium to upregulate
bIII-tubulin protein expression was independent of the passage
number of the LNCaP cells, as we obtained similar results using
either low- (P25) or high-passage (P80) cells (data not shown). In
addition, bIII-tubulin protein was expressed in various androgen-
independent human PCa cell lines, including 22Rv1, PC3 and
DU145 after western blot analysis of protein extracts from these
cells (Figure 2B). These data agree with a previous finding that
bIII-tubulin protein expression could be upregulated in LNCaP
cells cultured in the androgen-deficient medium for 4 days or after
transient suppression of androgen receptor expression using
siRNA (Wright et al, 2003). We then tested the effect of the AR
agonist, DHT on bIII-tubulin mRNA expression. To this end,
LNCaP cells were incubated for 10 days in an androgen-depleted
medium supplemented with 10nM DHT or with vehicle (ethanol,
EtOH). The expression of bIII-tubulin was partially abrogated in
chronic DHT-treated cells (Figure 2C).
Finally, we sought to extend this observation by analysing
bIII-tubulin expression in LNCaP tumours after xenografting into
athymic male nude mice. Five mice bearing tumours between 200
and 300mm
3 were killed and the tumour specimens were collected,
fixed and embedded for sectioning. In all, 10 other mice with
tumours of the same size were surgically castrated and then killed
at day 11 or 30 post castration to retrieve and process the tumours
for immunostaining. Both the pre-castrated and castrated levels of
bIII-tubulin were immunohistochemically analysed in various
LNCaP tumours using the same parameters that were used for
human tissues. Our analysis showed that the percentage of
bIII-tubulin-positive staining cells was significantly elevated in
tumour cells from castrated groups in a time-dependent manner.
Although only 2.7% of the tumour cells were found to be
bIII-tubulin positive in the tumour specimens obtained from the
pre-castrated group, 6.8 or 19.1% of tumour cells were considered
to be positive for bIII-tubulin at 11 or 30 days after castration,
respectively (Figure 3A and B). In summary, this study of cultured
and engrafted human prostate cancer cells supports the idea that
hormone therapy leading to the development of CRPC increases
the expression of bIII-tubulin in cancer cells.
DISCUSSION
This study for the first time provided definitive evidence that
bIII-tubulin is differentially expressed at the different stages of PCa
progression. One notable aspect of our observations with regard to
a relationship between bIII-tubulin expression and hormone
therapy for PCa is the possibility that bIII-tubulin expression
contributes to the aggressiveness of hormone-treated or castra-
tion-resistant PCa similar to the reports for other solid tumours.
However, studies investigating the functional ablation of
bIII-tubulin functions in this setting are required to demonstrate
conclusively its functional requirement for the emergence of
castration-resistant tumours. Additional studies are also required
to better define the mechanisms monitoring bIII-tubulin
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Figure 2 bIII-tubulin expression is regulated by androgen depletion in
LNCaP cultures and is expressed in androgen-independent PCa lines.
(A) Time-course expression of bIII-tubulin in LNCaPs cultivated in
androgen-reduced medium. At day 0, monolayer cultured LNCaP cells
were grown in the androgen-reduced medium. Each protein sample
(30mg) was resolved to SDS–PAGE, transferred onto a polyvinylidene
difluoride membrane (Millipore) and incubated with a monoclonal antibody
against bIII-tubulin or b-actin as an internal control. (B) The same
procedure was applied to examine bIII-tubulin expression in various PCa
cell lines (LNCaP, 22Rv1, DU145 and PC3) maintained in RPMI 1640
supplemented with 10% fetal bovine serum (FBS), AS, androgen-sensitive;
AI, androgen-independent. (C) bIII-tubulin mRNA is reduced on 10 days of
stimulation by 10nM DHT in LNCaP cells relative to the expression in cells
maintained in the androgen-reduced medium. Columns, mean±s.e.m.
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sexpression. Advanced PCa and castration-resistant PCa have been
associated with an attenuated androgen signalling signature
(Tomlins et al, 2007). This information further supports androgen
regulation and the increased expression of bIII-tubulin in
castration-resistant tumours. Interestingly, one recent study
provided evidence for a potential role of oestradiol and oestrogen
receptor (ER) in regulating bIII-tubulin in breast cancer cells
(Saussede-Aim et al, 2009). Although it remains to be determined
as to whether this regulation implies a genomic or a non-genomic
effect of ER, this observation could be of interest in PCa as
oestrogen-dependent signature has been linked to aggressive
characteristics in this tissue (Bonkhoff et al, 2001; Setlur et al,
2008). Future work will explore these questions. Recent data also
indicate that hypoxia may stimulate bIII-tubulin expression in the
A2780 ovarian cancer cells (Raspaglio et al, 2008). We previously
observed that hypoxia response can be altered in CRPC tumours
and cell lines (Anastasiadis et al, 2002). This may highlight an
alternative mechanism through which bIII-tubulin expression is
increased in those tumours.
In the hormone-naive PCa group, bIII-tubulin expression in
cancer cells was found to be restricted to a small number of
prostate cancer samples. Our results contrast with a previous
report showing that bIII-tubulin was consistently detectable in
HNPC, although at a relatively low level of expression that was
comparable with normal prostate epithelial cells (Ranganathan
et al, 1997). This difference might be attributable to a more
stringent immunostaining protocol. Future studies including
larger patient cohorts would help to determine whether
bIII-tubulin-positive tumours could represent a particular subtype
of PCa. In addition, it will be of particular interest to examine the
potential value of bIII-tubulin in predicting response to micro-
tubule-targeting agents in patients with prostate cancer. This
knowledge may be useful for a better management of patients in
that it could help to refine decision criteria and to better select
patients who are more likely to benefit from chemotherapy
regimens. We also believe that one appealing aspect of the
association between bIII-tubulin expression and hormone therapy
for PCa is the indication that anti-cancer chemotherapeutic drugs
that preferentially target microtubules with a bIII-tubulin compo-
nent might have greater value for the treatment of CRPC than
would docetaxel, which is currently recommended. Whereas we
already know that docetaxel therapy does provide some benefit for
CRPC patients, this benefit is generally limited to a few months of
additional survival (Petrylak et al, 2004; Tannock et al, 2004).
Clearly, the evidence that bIII-tubulin can modulate the sensitivity
of cancer cells to standard taxane-based cancer therapy gives
reason to consider whether other microtubule-targeting drugs with
greater efficacy against cancer cells that express bIII-tubulin might
be more effective in this regard. One candidate for this type of
approach may be the epothilone B analogue, ixabepilone, which is
being tested against various solid tumours with bIII-tubulin
expression (Rivera et al, 2008; Dumontet et al, 2009) and that has
already demonstrated activity in CRPCs, although it was with no
consideration of bIII-tubulin status (Galsky et al, 2005). Our
results give strong reason to consider bIII-tubulin status and to
further test this therapeutic for CRPC patients.
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Figure 3 bIII-tubulin expression increases after androgen depletion in
LNCaP xenografts. (A) Representative immunostains in LNCaP xenografts
with antibody to bIII-tubulin. Immunohistochemical stains show weak or
absent staining for LNCaP tumours from a non-castrated mouse (left),
while a high proportion of positive cells with intense staining is detected 30
days after castration (right); original magnification,  200. (B) Means of
positive cells for bIII-tubulin in each group. Kruskal–Wallis test (P¼0.002)
and Mann–Whitney test were used for statistical analysis of the
immunohistochemistry scoring results. Columns mean; bars, s.e. *Po0.05.
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